Electromedical Technologies Inc (EMED)

[Winsmore]

TeacherMan, hope this info helps. Again, it's with the help of A.I. for your evaluation.

While your theories align with aggressive corporate restructuring tactics, the mechanism to achieve a zero-dilution outcome for existing Electromedical Technologies (EMED) common shareholders is incredibly narrow.

If Lionheart uses a manufactured default to strip EMED of its assets right before an IPO, it creates a massive litigation risk. Legacy noteholders and common shareholders can sue Lionheart for breach of fiduciary duty, fraudulent conveyance, and predatory lending. Institutional investors rarely touch IPOs with active or imminent shareholder litigation.

Evaluate the Two Restructuring Scenarios

Scenario A: The Loan Paid Off Noteholders (The Hidden Settlement Theory)

How it works: EMED used the cash proceeds from the $500,000 loan to quietly buy back, settle, or satisfy the $514,000 legacy convertible note obligation before it could convert into 3.1 billion shares.

The S-1 Impact: Clean and positive. Lionheart can file an S-1 showing a streamlined target acquisition with a known, fixed-dollar debt profile ($500k + interest/penalties) rather than a hyper-dilutive, toxic equity overhang.

The Missing Link: A cash settlement of debt must legally be disclosed under "Subsequent Events" or "Liquidity and Capital Resources" in public financial filings. If EMED's Q1 2026 report still reflects the $514,000 noteholder balance alongside the defaulted $500,000 loan, the overhang is not gone. A company cannot selectively hide the retirement of a major liability to mask a rollup, as doing so violates basic SEC financial reporting guidelines.


Scenario B: "Loan-to-Own" Asset Seizure (The Foreclosure Theory)

How it works: Lionheart intentionally structured the $500,000 loan with aggressive terms (20% interest for 4 months + immediate default penalties) and secured it with "all of the assets of the company." Because EMED defaulted on April 1, 2026, Lionheart now holds the legal right to foreclose on EMED's core IP, manufacturing tech, and inventory.

The S-1 Impact: Disastrous for public markets. If Lionheart seizes the assets and leaves EMED as an empty shell, they effectively wipe out the 3.1-billion-share note overhang—but they also wipe out your common shares. The "empty shell" EMED left behind would still hold the $514,000 debt, while Lionheart goes public with the clean operational assets.



Analyze How This Looks on a Form S-1

If Lionheart is preparing an independent IPO in 2026, the SEC requires rigorous disclosure regarding Related Party Transactions and asset acquisitions.

Transaction Method - Appearance on S-1 / Investor Perception

1. Legitimate Debt Refinancing: Highly Favorable. Standard corporate rollup behavior. It shows Lionheart acting as a financial backer to stabilize a target entity before bringing it public.

2. Strategic Loan Forgiveness: Favorable. If Lionheart converts the $500,000 loan into equity as part of the formal rollup agreement, public investors view it as a committed parent company reinforcing its subsidiary.

3. Asset Seizure via Default: Extremely Negative (Red Flag). If Lionheart uses a manufactured default to strip EMED of its assets right before an IPO, it creates a massive litigation risk. Legacy noteholders and common shareholders can sue Lionheart for breach of fiduciary duty, fraudulent conveyance, and predatory lending. Institutional investors rarely touch IPOs with active or imminent shareholder litigation



Action Plan to Protect and Verify Your Position

To determine if you are facing a massive dilution event or a complete asset wipeout, execute the following forensic steps:

1. Audit the Q1 2026 Balance Sheet: Open EMED’s 2026 Q1 report. Check the liabilities section specifically for the line item tracking "Convertible Notes Payable." If that $514,000 is still listed, the overhang remains active and dangerous.

2. Review the "Related Party" Disclosures: Look at who the "company" is behind the $500,000 loan. If it is officially unmasked as Lionheart or a Lionheart executive, strict regulatory rules bind their ability to arbitrarily seize assets without public disclosure.

3. Monitor Default Notices: Watch the OTC Markets disclosure stream for a "Notice of Foreclosure" or "UCC-1 Financing Statement" enforcement. If Lionheart moves to seize the assets under the security agreement, common equity value drops to near-zero immediately.

4. Evaluate the Rollup Agreement Terms: A legitimate rollup will dictate exactly what happens to EMED stock (e.g., a 1-for-X share swap into Lionheart equity).

If a formal merger agreement is filed, look for a clause detailing the "treatment of outstanding convertible debt."

Your next logical step is to cross-reference the total liability balance from the 2025 annual report against the newly issued 2026 Q1 report to verify if the $514,000 noteholder debt was actively reduced or if it is sitting parallel to the defaulted $500,000 loan.